Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a NetworkNewsAudio editorial highlighting its novel approach to treating multiple sclerosis (MS). The audio press release, titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” underscores the company’s lead candidate, Lucid-MS, a patented first-in-class drug designed to directly target the myelin sheath. According to the company, Lucid-MS aims to prevent, stop, and potentially reverse myelin degradation, the underlying cause of MS. This comes at a time when the global MS therapeutics market is projected to reach $38.62 billion by 2030, reflecting a growing need for therapies that go beyond symptom management and address the disease’s root cause.
Multiple sclerosis is a chronic neurodegenerative disease that affects millions worldwide, with most current treatments focused on managing symptoms or reducing relapse rates rather than halting or reversing disease progression. Quantum BioPharma’s Lucid-MS is positioned as a disease-modifying treatment that could alter the course of MS by targeting the myelin sheath directly. The company’s preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, a significant advancement over existing therapies. This innovation is particularly important given the substantial unmet need for treatments that can modify the disease itself, not just alleviate symptoms.
The implications of this development are far-reaching. For patients, a therapy that can potentially reverse myelin damage could mean improved quality of life, reduced disability, and slower disease progression. For the pharmaceutical industry, Lucid-MS represents a new class of drugs that could set a new standard of care in MS treatment. The global MS therapeutics market is projected to reach $38.62 billion by 2030, indicating strong demand for innovative therapies. Quantum BioPharma’s focus on this area positions it to capture a significant share of this growing market, should Lucid-MS prove successful in clinical trials.
Quantum BioPharma is a biopharmaceutical company building a portfolio of assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS as its lead compound. The company also holds a stake in Unbuzzd Wellness Inc., which markets an over-the-counter version of UNBUZZD, and retains royalty payments from sales. As of March 31, 2026, Quantum owns 19.84% of Unbuzzd, with a royalty structure that includes 7% of sales until $250 million is reached, then 3% in perpetuity. Quantum retains 100% rights to develop similar products for pharmaceutical and medical uses.
The recent audio feature highlights the urgency of addressing the massive unmet need in multiple sclerosis. With the MS therapeutics market expanding, Quantum BioPharma’s Lucid-MS could play a pivotal role in transforming treatment paradigms. The company continues to advance its research, and the industry will be watching closely as Lucid-MS moves through development stages. For more information, visit the company’s newsroom at https://nnw.fm/QNTM.
This news matters because it sheds light on a potential breakthrough in MS treatment that could significantly improve patient outcomes and reshape the competitive landscape of the neurodegenerative disease therapeutics market. As the global population ages and MS diagnoses rise, the demand for effective disease-modifying therapies will only increase, making Quantum BioPharma’s research particularly timely.
